Selected Grants
1/3 CTSA UM1 at Duke University
ResearchFaculty Member · Awarded by National Institutes of Health · 2025 - 2032Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST). A cluster randomized trial of point-of-care hepatitis C testing and treatment among key populations
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030Aligos ALG-184-202_HBV A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult
Clinical TrialPrincipal Investigator · Awarded by Aligos Therapeutics, Inc. · 2025 - 2030Social Determinants of Disparities in Inflammatory Bowel Disease
ResearchPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2023 - 2028Duke Training Grant in Digestive Diseases and Nutrition
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 1988 - 2027A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Clinical TrialPrincipal Investigator · Awarded by Mirum Pharmaceuticals, Inc. · 2021 - 2027Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026Health Equity in Colon Cancer Screening
ResearchPrincipal Investigator · Awarded by American Board of Internal Medicine Foundation · 2023 - 2025VTEU Task Order 4 - Cost to Complete
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2024 - 2025Alphapump system in the treatment of refractory or recurrent ascites: a muticenter single arm within subject crossover design pivotal study (The POSEIDON Study)
Clinical TrialPrincipal Investigator · Awarded by Sequana Medical NV · 2020 - 2024VTEU 13-0053 FY 2020 Option 1-Protocol Implementation
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2014 - 2024A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen with out Interferon for Chronic Hepatitis C Infection in Gilead Sponsored Trials.
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2015 - 2022The Impact of Race, Ethnicity, and Socioeconomic Status on Listing for Liver Transplant after Referral
ResearchPrincipal Investigator · Awarded by American Association for the Study of Liver Diseases · 2018 - 2020Gilead HCV Heart and Lung - A Multicenter, open-label study of Harvoni® (sofosbuvir-ledipasvir fixed dose combination) in subjects infected with chronic hepatitis C and advanced heart failure or lung disease
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020External Relationships
- Gilead pharma
- Health monitor
- Ipsen
- Janssen Pharmaceuticals (Johnson & Johnson)
- Pluto Health
- TruLab
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.